STOCK TITAN

[Form 4] Pulmonx Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

David Aaron Lehman, identified as General Counsel and officer of Pulmonx Corporation (ticker LUNG), reported four separate non-derivative stock dispositions on 09/02/2025. The Form 4 shows Mr. Lehman sold 929, 3,541, 2,068 and 3,231 shares, each at $1.60 per share. Each sale is explained as occurring to cover tax withholding obligations tied to Restricted Stock Units that vested from grants dated March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025, respectively. The filing reports the reporting-person’s beneficial ownership following these transactions as 272,110, 268,569, 266,501 and 263,270 shares (direct ownership) after each reported disposition. The Form 4 is signed by Mr. Lehman on 09/03/2025.

David Aaron Lehman, indicato come General Counsel e dirigente di Pulmonx Corporation (ticker LUNG), ha segnalato quattro distinte cessioni non derivate di azioni in data 02/09/2025. Il modulo Form 4 indica che il Sig. Lehman ha venduto rispettivamente 929, 3.541, 2.068 e 3.231 azioni, ciascuna a $1,60 per azione. Ciascuna vendita è motivata dalla necessità di coprire imposte e ritenute collegate a Restricted Stock Units maturate da assegnazioni datate 1 marzo 2022, 1 marzo 2023, 1 marzo 2024 e 3 marzo 2025, rispettivamente. Dopo ciascuna operazione, la dichiarazione riporta la proprietà beneficiaria del dichiarante pari a 272.110, 268.569, 266.501 e 263.270 azioni (proprietà diretta). Il Form 4 è firmato dal Sig. Lehman il 03/09/2025.

David Aaron Lehman, identificado como Asesor General y ejecutivo de Pulmonx Corporation (ticker LUNG), reportó cuatro ventas no derivadas de acciones el 02/09/2025. El Formulario 4 muestra que el Sr. Lehman vendió 929, 3.541, 2.068 y 3.231 acciones, cada una a $1,60 por acción. Cada operación se explica como realizada para cubrir obligaciones fiscales vinculadas a Restricted Stock Units que se hicieron efectivas por otorgamientos con fecha 1 de marzo de 2022, 1 de marzo de 2023, 1 de marzo de 2024 y 3 de marzo de 2025, respectivamente. La presentación informa la propiedad beneficiosa del declarante tras estas transacciones como 272.110, 268.569, 266.501 y 263.270 acciones (propiedad directa) después de cada disposición informada. El Form 4 está firmado por el Sr. Lehman el 03/09/2025.

David Aaron Lehman은 Pulmonx Corporation(티커 LUNG)의 법률담당총괄(General Counsel) 겸 임원으로 보고되었으며, 2025-09-02에 4건의 비파생 주식 처분을 보고했습니다. Form 4에는 Lehman 씨가 각각 929, 3,541, 2,068, 3,231주를 주당 $1.60에 매도한 것으로 나와 있습니다. 각 매도는 각각 2022년 3월 1일, 2023년 3월 1일, 2024년 3월 1일, 2025년 3월 3일에 부여된 Restricted Stock Units의 성과·지급(vesting)으로 인한 세금 원천징수 의무를 충당하기 위해 이루어졌다고 설명되어 있습니다. 각 처분 후 보고자의 실소유 지분은 각각 272,110, 268,569, 266,501, 263,270주(직접 소유)로 기재되어 있습니다. Form 4는 Lehman 씨가 2025-09-03에 서명했습니다.

David Aaron Lehman, désigné comme General Counsel et dirigeant de Pulmonx Corporation (symbole LUNG), a déclaré quatre cessions distinctes d'actions non dérivées le 02/09/2025. Le formulaire Form 4 indique que M. Lehman a vendu 929, 3 541, 2 068 et 3 231 actions, chacune à 1,60 $. Chaque vente est expliquée comme visant à couvrir les obligations de retenue fiscale liées à des Restricted Stock Units ayant acquis le droit à partir des attributions datées du 1er mars 2022, 1er mars 2023, 1er mars 2024 et 3 mars 2025, respectivement. Après chaque opération, la déclaration reporte la détention bénéficiaire du déclarant à 272 110, 268 569, 266 501 et 263 270 actions (possession directe). Le Form 4 est signé par M. Lehman le 03/09/2025.

David Aaron Lehman, ausgewiesen als General Counsel und leitender Angestellter von Pulmonx Corporation (Ticker LUNG), meldete vier separate nicht-derivative Aktienveräußerungen am 02.09.2025. Das Formular Form 4 weist aus, dass Herr Lehman jeweils 929, 3.541, 2.068 und 3.231 Aktien zu je $1,60 verkauft hat. Jede Veräußerung diente der Abdeckung von steuerlichen Abzugsverpflichtungen im Zusammenhang mit Restricted Stock Units, die aus Zuschüssen vom 1. März 2022, 1. März 2023, 1. März 2024 und 3. März 2025 fällig wurden. Nach den jeweiligen Transaktionen wird das wirtschaftliche Eigentum des Berichtenden mit 272.110, 268.569, 266.501 und 263.270 Aktien (direkter Besitz) angegeben. Das Form 4 ist von Herrn Lehman am 03.09.2025 unterschrieben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider share sales to cover tax withholding on vested RSUs; transparent and typical for executives.

The Form 4 discloses small, mechanically driven dispositions tied explicitly to tax withholding for RSU vesting across four grant years. The transactions are reported contemporaneously and include post-transaction beneficial ownership figures, supporting governance transparency. There is no indication of discretionary, opportunistic selling or of transactions outside the stated withholding purpose. For shareholders, these actions reflect compensation settlement mechanics rather than a change in insider conviction.

TL;DR: Insignificant volume insider sales at $1.60 to satisfy taxes; immaterial to capitalization and valuation.

The aggregate number of shares disposed (9,769 shares) and the uniform per-share price indicate tax-withholding dispositions tied to RSU vesting. The filing provides clear quantities and resulting direct ownership balances, enabling straightforward updates to insider ownership metrics. Absent other disclosures, these transactions are unlikely to affect market perception or company valuation materially.

David Aaron Lehman, indicato come General Counsel e dirigente di Pulmonx Corporation (ticker LUNG), ha segnalato quattro distinte cessioni non derivate di azioni in data 02/09/2025. Il modulo Form 4 indica che il Sig. Lehman ha venduto rispettivamente 929, 3.541, 2.068 e 3.231 azioni, ciascuna a $1,60 per azione. Ciascuna vendita è motivata dalla necessità di coprire imposte e ritenute collegate a Restricted Stock Units maturate da assegnazioni datate 1 marzo 2022, 1 marzo 2023, 1 marzo 2024 e 3 marzo 2025, rispettivamente. Dopo ciascuna operazione, la dichiarazione riporta la proprietà beneficiaria del dichiarante pari a 272.110, 268.569, 266.501 e 263.270 azioni (proprietà diretta). Il Form 4 è firmato dal Sig. Lehman il 03/09/2025.

David Aaron Lehman, identificado como Asesor General y ejecutivo de Pulmonx Corporation (ticker LUNG), reportó cuatro ventas no derivadas de acciones el 02/09/2025. El Formulario 4 muestra que el Sr. Lehman vendió 929, 3.541, 2.068 y 3.231 acciones, cada una a $1,60 por acción. Cada operación se explica como realizada para cubrir obligaciones fiscales vinculadas a Restricted Stock Units que se hicieron efectivas por otorgamientos con fecha 1 de marzo de 2022, 1 de marzo de 2023, 1 de marzo de 2024 y 3 de marzo de 2025, respectivamente. La presentación informa la propiedad beneficiosa del declarante tras estas transacciones como 272.110, 268.569, 266.501 y 263.270 acciones (propiedad directa) después de cada disposición informada. El Form 4 está firmado por el Sr. Lehman el 03/09/2025.

David Aaron Lehman은 Pulmonx Corporation(티커 LUNG)의 법률담당총괄(General Counsel) 겸 임원으로 보고되었으며, 2025-09-02에 4건의 비파생 주식 처분을 보고했습니다. Form 4에는 Lehman 씨가 각각 929, 3,541, 2,068, 3,231주를 주당 $1.60에 매도한 것으로 나와 있습니다. 각 매도는 각각 2022년 3월 1일, 2023년 3월 1일, 2024년 3월 1일, 2025년 3월 3일에 부여된 Restricted Stock Units의 성과·지급(vesting)으로 인한 세금 원천징수 의무를 충당하기 위해 이루어졌다고 설명되어 있습니다. 각 처분 후 보고자의 실소유 지분은 각각 272,110, 268,569, 266,501, 263,270주(직접 소유)로 기재되어 있습니다. Form 4는 Lehman 씨가 2025-09-03에 서명했습니다.

David Aaron Lehman, désigné comme General Counsel et dirigeant de Pulmonx Corporation (symbole LUNG), a déclaré quatre cessions distinctes d'actions non dérivées le 02/09/2025. Le formulaire Form 4 indique que M. Lehman a vendu 929, 3 541, 2 068 et 3 231 actions, chacune à 1,60 $. Chaque vente est expliquée comme visant à couvrir les obligations de retenue fiscale liées à des Restricted Stock Units ayant acquis le droit à partir des attributions datées du 1er mars 2022, 1er mars 2023, 1er mars 2024 et 3 mars 2025, respectivement. Après chaque opération, la déclaration reporte la détention bénéficiaire du déclarant à 272 110, 268 569, 266 501 et 263 270 actions (possession directe). Le Form 4 est signé par M. Lehman le 03/09/2025.

David Aaron Lehman, ausgewiesen als General Counsel und leitender Angestellter von Pulmonx Corporation (Ticker LUNG), meldete vier separate nicht-derivative Aktienveräußerungen am 02.09.2025. Das Formular Form 4 weist aus, dass Herr Lehman jeweils 929, 3.541, 2.068 und 3.231 Aktien zu je $1,60 verkauft hat. Jede Veräußerung diente der Abdeckung von steuerlichen Abzugsverpflichtungen im Zusammenhang mit Restricted Stock Units, die aus Zuschüssen vom 1. März 2022, 1. März 2023, 1. März 2024 und 3. März 2025 fällig wurden. Nach den jeweiligen Transaktionen wird das wirtschaftliche Eigentum des Berichtenden mit 272.110, 268.569, 266.501 und 263.270 Aktien (direkter Besitz) angegeben. Das Form 4 ist von Herrn Lehman am 03.09.2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lehman David Aaron

(Last) (First) (Middle)
C/O PULMONX CORPORATION
700 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
GENERAL COUNSEL
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 S(1) 929 D $1.6 272,110 D
Common Stock 09/02/2025 S(2) 3,541 D $1.6 268,569 D
Common Stock 09/02/2025 S(3) 2,068 D $1.6 266,501 D
Common Stock 09/02/2025 S(4) 3,231 D $1.6 263,270 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.
2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
/s/ David Aaron Lehman 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Pulmonx Corporation (LUNG)?

The Form 4 was filed by David Aaron Lehman, identified as General Counsel and an officer of Pulmonx Corporation.

What transactions did the reporting person disclose on 09/02/2025?

Mr. Lehman disclosed four sales of common stock on 09/02/2025: 929, 3,541, 2,068, and 3,231 shares, each at $1.60 per share.

Why were the shares sold according to the Form 4?

Each sale was executed to cover tax withholding obligations arising from RSUs that vested from grants dated March 1, 2022; March 1, 2023; March 1, 2024; and March 3, 2025.

What were the reporting person’s beneficial ownership balances after the transactions?

The Form 4 reports direct beneficial ownership following the reported transactions as 272,110, 268,569, 266,501, and 263,270 shares, respectively.

When was the Form 4 signed by the reporting person?

The Form 4 bears the signature of David Aaron Lehman dated 09/03/2025.
Pulmonx Corp

NASDAQ:LUNG

LUNG Rankings

LUNG Latest News

LUNG Latest SEC Filings

LUNG Stock Data

70.90M
39.05M
4.35%
89.54%
3.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY